CareDx partners with 10x Genomics on transplant rejection research program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for strongest quarter in years as risk appetite holds despite US-Iran war
- Dollar pushes higher, yen sinks to 40-year low
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Logitech dips as BofA downgrades stock on demand outlook concerns
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
January 7, 2026 7:05 AM ESTCollaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling
BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ... More
